Gambro AB


in
Gambro AB announced the start of a strategic alliance with Sandoz, Inc. Both companies have agreed to cooperate in the launch of Sandoz' biosimilar Binocrit, the first biosimilar epoetin alfa which has been approved by the European Commission in August this year. This alliance will use the leading position of Gambro in the treatment of Chronic Kidney failure through dialysis and the pioneering position of Sandoz in the development and production of biosimilar pharmaceuticals to enhance the care of patients.